The soluble interleukin-2 receptor as a marker for human neoplasia and immune status.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

The soluble interleukin-2 receptor as a marker for human neoplasia and immune status.

Cancer Cells. 1991 Dec;3(12):471-9. Unique Identifier : AIDSLINE MED/92313794
Zerler B; Molecular Therapeutics, Inc., Miles Research Center, West Haven,; Connecticut 06516.

Abstract: Activation of T cells is associated with a dramatic increase in expression of the interleukin-2 receptor. In addition to the intact receptor found at the cell surface, activated T cells produce a truncated form of the receptor (sIL-2R) that is secreted as a soluble molecule. Patients with neoplastic disease or diseases involving immune activation exhibit markedly elevated serum levels of sIL-2R. Although the functional significance of sIL-2R is unknown, the ability to measure this parameter rapidly and accurately in serum samples makes it a potentially useful index for monitoring disease activity. Recent studies indicate that a rise in serum levels of sIL-2R in apparently healthy individuals could be an important early signal of neoplastic, autoimmune, or inflammatory disease. Moreover, subsequent to diagnosis, serum levels of sIL-2R appear to be a reliable indicator of tumor burden and therapeutic response for many patients with leukemia and lymphoma, an indicator of metastasis for patients with solid tumors, and an indicator of exacerbation and clinical response in patients with diseases associated with immune activation.

Keywords: Adult Autoimmune Diseases/*BLOOD Biological Markers/BLOOD Child, Preschool Female Human HIV Infections/BLOOD HTLV-I Infections/BLOOD Infant Inflammation/*BLOOD Leukemia/BLOOD/IMMUNOLOGY *Lymphocyte Transformation Lymphoma/BLOOD/IMMUNOLOGY Male Neoplasm Metastasis Neoplasms/*BLOOD/IMMUNOLOGY Receptors, Interleukin-2/*ANALYSIS T-Lymphocytes/IMMUNOLOGY/SECRETION Tumor Markers, Biological/*BLOOD JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
921030
M92A1000

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .